NIPRO CORPORATION (8086) Stock Price

Nipro operates three business segments: Medical Devices, Pharmaceuticals, and Pharma Packaging. These segments align with the segment information presented in the company's consolidated financial statements.

In the Medical Devices segment, Nipro manufactures and sells medical devices and consumables. Specific products include blood dialysis equipment, syringes, and catheters. Through these offerings, the company provides high-quality medical products to healthcare institutions and patients.

In the Pharmaceuticals segment, Nipro manufactures and sells pharmaceutical products. The company focuses primarily on generic pharmaceuticals and offers products across a wide range of therapeutic areas, contributing to reduced healthcare costs.

In the Pharma Packaging segment, Nipro manufactures packaging materials for pharmaceuticals. The company supplies glass vials, ampoules, and plastic packaging materials, supporting pharmaceutical product quality and safety.

Nipro is advancing product development grounded in technological innovation to improve patient quality of life and meet healthcare facility needs. The company aims to expand its global market share by adopting a local production for local consumption concept, thereby enhancing production capacity and quality. Through three business segments—medical devices, pharmaceuticals, and pharma packaging—Nipro focuses on developing safe, user-centric products.

In domestic healthcare-related operations, Nipro is opening new distribution channels, streamlining product lineups, and promoting healthcare digital transformation. In the generic pharmaceutical business, the company prioritizes stable supply and quality assurance while strengthening partnerships with major wholesalers. Overseas, Nipro enhances the value of core products through academic activities and technical sales to improve profitability.

As a product strategy, Nipro is expanding into new therapeutic areas, and as a regional strategy, it aims to increase market share in the Americas and Asia-Pacific. Particularly in the dialysis market, the company is expanding its dialyzer lineup and rolling out new models of high-performance dialysis equipment, while launching NephroFlow™.

Nipro targets consolidated net sales of 1 trillion yen by fiscal year 2030 and continues growth investments. The company is improving operating profit margins and free cash flow to strengthen its financial foundation. Key priorities include raising average selling prices and promoting digital transformation across all products to achieve greater efficiency and labor savings.

Nipro regards stable supply of medical devices and pharmaceuticals as its primary mission. To address rising manufacturing costs and healthcare cost containment policies, the company is working to secure cost competitiveness. Nipro is addressing supply chain risks and logistics challenges while pursuing quality improvement and stable supply.